Research
Published · Updated · 1 min read
Intravitreal topotecan: rabbit retinal ultrastructural changes at different single doses
What it means for practice
These preclinical findings suggest potential for topotecan in intravitreal chemotherapy for retinoblastoma but do not establish safe doses for use in humans.
Summary
What was studied
A study in 12 Chinchilla rabbits assessed the effects of different single doses of intravitreal topotecan on retinal ultrastructure. Animals were divided into groups receiving different doses of the drug; the control group received saline. The study concerned retinal structural changes in an experimental model rather than clinical outcomes of retinoblastoma treatment in humans.
Key findings
Doses of 20–30 µg caused minimal reversible retinal changes. Doses of 40–50 µg produced more pronounced hydropic dystrophy. A dose of 60 µg caused initial alterations in neural organelles. The abstract thus describes different ultrastructural changes depending on the administered topotecan dose.
Implications and limits
The authors suggest lower toxicity with topotecan than with melphalan and potential as a safer option for intravitreal chemotherapy in retinoblastoma. However, the abstract does not describe a direct comparison with melphalan, assessment timing, or the number of animals in each group. These preclinical observations do not establish safe doses for humans.
Source
-
Effect of various single doses of intravitreal topotecan on the ultrastructure of the rabbit retina.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
